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Abstract:  
Background & Aims: Fecal microbiota transplantation (FMT) is recommended for recurrent 
Clostridioides difficile infection (CDI). FMT cures nearly 80% of patients with severe or fulminant CDI 
(SFCDI) when utilized in a sequential manner. We compared outcomes of hospitalized patients before 
and after implementation of an FMT program for SFCDI and investigated whether the changes could be 
directly attributed to the FMT program. 
Methods: We performed a retrospective analysis of characteristics and outcomes of patients 
hospitalized for SFCDI (430 hospitalizations) at a single center, from January 2009 through December 
2016. We performed subgroup analyses of 199 patients with fulminant CDI and 110 patients with 
refractory SFCDI (no improvement after 5 or more days of maximal anti-CDI antibiotic therapy). We 
compared CDI-related mortality within 30 days of hospitalization, CDI-related colectomy, length of 
hospital stay, and readmission to the hospital within 30 days before (2009–2012) vs after (2013–2016) 
implementation of the inpatient FMT program.  
Results: CDI-related mortality and colectomy were lower after implementation of the FMT program. 
Overall, CDI-related mortality was 10.2% before the FMT program was implemented vs 4.4% after 
(P=.02). For patients with fulminant CDI, CDI-related mortality was 21.3% before the FMT program was 
implemented vs 9.1% after (P=.015). For patients with refractory SFCDI, CDI-related mortality was 43.2% 
before the FMT program vs 12.1% after (P < .001).  
The FMT program significantly reduced CDI-related colectomy in patients with SFCDI (6.8% before vs 
2.7% after; P=.041), in patients with fulminant CDI (15.7% before vs 5.5% after; P=.017), and patients 
with refractory SFCDI (31.8% vs 7.6%; P = .001). The effect of FMT program implementation on CDI-
related mortality remained significant for patients with refractory SFCDI after we accounted for the 
underlying secular trend (odds ratio, 0.09 for level change; P=.023). 
Conclusions: An FMT program significantly decreased CDI-related mortality among patients hospitalized 
with refractory SFCDI. 
KEY WORDS: gut microbe, dysbiosis, bacteria, treatment 
What You Need to Know 
Background: Fecal microbiota transplant (FMT) is an effective treatment for severe or fulminant 
Clostridioides difficile infection (SFCDI). We compared outcomes of hospitalized patients before 
vs after implementation of an FMT program for SFCDI and investigated whether changes could 
be directly attributed to the FMT program.  
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Findings: In a comparison of 430 hospitalized patients with SFCDI, we found that a subgroup of 
patients with SFCDI that was refractory to maximum antibiotic treatment for 5 or more days had 
a significant decrease in CDI-related mortality after the FMT program began, after we accounted 
for demographic features.  
 





Clostridioides difficile is the leading cause of nosocomial diarrhea in the world.1,2 Approximately 8% 
of patients with Clostridioides difficile infection (CDI) develop severe or fulminant (formerly severe-
complicated) disease leading to an elevated risk for toxic megacolon, multi-organ failure, and mortality.3  
The Infectious Disease Society of America (IDSA) recommends vancomycin as first-line therapy for all 
categories of CDI severity,4 while surgery should be considered for severe or fulminant CDI (SFCDI) 
refractory to maximum medical therapy.5 Despite improvements in surgical technique,6 clinical 
prediction models for poor surgical outcomes,7 and conceptual changes in the timing of surgery,8,9 30-
day post-colectomy mortality rates are upwards of 40%.10,11  
Fecal microbiota transplantation (FMT) is recommended therapy for recurrent CDI, with cure rates 
above 80%,12-17 and decreased relapse compared to anti-CDI antibiotic therapy.15,18,19 Several studies 
have also demonstrated FMT’s efficacy in treating SFCDI, with 91% cure for severe CDI and 66% for 
fulminant CDI.20 Cure rates for fulminant CDI increase to nearly 90% when FMTs are  performed in a 
sequential manner in combination with vancomycin.21,22 More importantly, medical centers in Italy and 
France report decreasing mortality and colectomy rates in SFCDI after FMT availability.23,24 
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This study aimed to evaluate changes in patient outcomes before and after implementation of an 
FMT program for patients hospitalized with SFCDI, and to determine if such changes could be directly 
attributed to the FMT program.  
Materials and Methods 
Data Collection 
This retrospective cohort study included hospitalized adults (age ≥18 years) with a diagnosis of 
severe or fulminant CDI between January 2009 and December 2016 at Indiana University Hospital. 
Hospital admissions with ICD-9 008.45 and ICD-10 A04.7 diagnosis codes were identified from an 
institutional electronic medical record system (Cerner) and additional data collected via individual chart 
review. This study was approved by the Institutional Review Board at Indiana University. Patient 
characteristics included age at the time of hospitalization, sex, Charlson Comorbidity Index,25 
immunocompromised state, and underlying inflammatory bowel disease (IBD). CDI characteristics 
included white blood cell count, serum albumin concentration, number of previous CDI episodes, as well 
as evidence of CDI-related end-organ damage such as hypotension, vasopressor use, mental status 
change, acute kidney injury, ileus, toxic megacolon, mechanical ventilation, and/or admission to the 
intensive care unit (ICU). Finally, FMT-related variables were also recorded including donor type 
(patient-selected versus universal), method of delivery (enema versus colonoscopy), number of FMTs 
performed during hospitalization, and presence of pseudomembranous colitis at time of colonoscopy.  
Definitions 
We classified CDI into severe CDI or fulminant CDI based on the IDSA guidelines.4 We defined 
refractory SFCDI as patients with severe or fulminant CDI who failed to respond (progressive worsening 
or no significant improvement in objective clinical parameters such as leukocytosis, diarrhea, 
hypotension, vasopressor requirement) to maximum anti-CDI antimicrobial therapy via PO vancomycin 
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for at least 5 days. In the event of ileus and/or toxic megacolon, rectal vancomycin and IV metronidazole 
were also included in the regimen. 
FMT Treatment Protocol 
After inpatient FMT program availability in 2013, patients with SFCDI were offered FMT if they 
had evidence of refractory SFCDI or had ≥2 recurrences of CDI.  Patients with refractory SFCDI received 
our previously published inpatient sequential FMT protocol, which combines oral vancomycin and 
pseudomembrane-driven sequential FMT(s).26 The treatment algorithm can be found in Supplementary 
materials. The majority of our patients received frozen-thawed stool provided by a stool bank 
(OpenBiome, Cambridge, MA, USA), which employs a standardized and rigorous screening process for 
donors.27 
Outcomes 
Patients were grouped into a pre-FMT (2009-2012) and post-FMT (2013-2016) time period. 
Additionally, we performed analyses on two subgroups of patients: 1) fulminant CDI patients and 2) 
refractory SFCDI patients. 
The primary study outcome was 30-day CDI-related mortality (in-hospital death and death within 30 
days post-discharge were variables captured by institutional medical records and our prospectively 
collected FMT database). Secondary outcome measures included CDI-related colectomy during 
hospitalization, length of stay (LOS), and 30-day readmission. Re-admissions were documented and 
treated as a distinct admission event. Hospitalizations with in-hospital patient death were excluded from 
the analysis of 30-day readmission. This resulted in a total of 72 SFCDI hospitalizations being excluded 
for the analysis of 30-day readmission, including 52 fulminant CDI hospitalizations, and 36 refractory 
SFCDI hospitalizations. The clinical course of each patient who died or underwent colectomy was 




 Patient and disease characteristics at the time of hospital admission were summarized using 
mean values with standard deviation or median values with interquartile range (25th to 75th percentile) 
for continuous variables; proportions were used for categorical values. To compare patient 
characteristics before and after FMT program implementation, the two-sample t-test or Wilcoxon rank 
sum test was used for continuous variables while Pearson’s chi-square test or Fisher’s exact test was 
used for categorical variables. Differences in outcomes between the pre- and post-FMT time periods 
were compared in a similar fashion.  
 Segmented logistic regression (SLR) was used to evaluate whether differences in outcomes 
between time periods could be attributed to FMT program implementation or were due to secular 
changes (eg changes that would have happened even without the FMT program). Specifically, separate 
intercepts and slopes are quantified in each time period and the effect of the FMT program is then 
indicated by the differences in intercept and/or slope. A difference in intercept (i.e. level change) implies 
an immediate change in outcomes at time of FMT program implementation. A difference in slope (i.e. 
slop change) implies a gradual effect of the FMT program over time.28 Differences in intercepts and 
slopes were estimated based on the segmented logistic regression and tested using the Wald test. All 
statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, N.C.).   
Results  
Patient Characteristics 
 Among 430 hospital admissions with severe or fulminant CDI, 205 admissions occurred before 
(pre-FMT) and 225 after FMT program implementation (post-FMT). Patients from the two time periods 
were comparable except for a significant difference in the percentage of patients with IBD and median 
number of prior CDI episodes (Table 1) 
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Upon subgroup analysis, there were 199 hospitalizations for fulminant CDI; comparison of 
patient characteristics among 89 pre-FMT and 110 post-FMT hospitalizations only found a difference in 
the median number of prior CDI episodes (Table 2). In another subgroup consisting of 110 refractory CDI 
hospitalizations, comparison of 44 pre-FMT and 66 post-FMT patients revealed that the post-FMT group 
had a higher median number of prior CDI episodes and a lower proportion of mechanical ventilation and 
ICU stay (Table 3). 
FMT Characteristics 
 A total of 50 patients received FMT due to refractory SFCDI. This amounted to 94 total FMTs 
delivered, 98% (92/94) via colonoscopy and 90.4% (85/94) with frozen stool via non-directed donor. 
Pseudomembranes were identified during 63.8% (60/94) of the FMTs. A median of 2 FMTs (IQR 1-2) was 
given to each patient who underwent this sequential protocol. FMT was also given to 21 other patients 
with non-refractory SFCDI for alternate indications including multiply recurrent CDI (n = 18), persistent 
ileus (n =2), and pseudomembranes during colonoscopy for restaging of IBD (n = 1).  
Of the 16 patients with refractory SFCDI in the post-FMT period who did not undergo FMT, 6 
underwent colectomy (5 survived, 1 died within 30 days), 3 continued with medical therapy and 
survived, and the remaining 7 died due to withdrawal of care or anatomic issues precluding delivery of 
FMT (obstructing distal colon cancer not allowing passage of an endoscope). 
Outcomes 
 A summary of outcomes and comparison of pre-FMT to post-FMT time periods can be found in 
Table 4. Outcome trends over time are depicted in Figure 1 for CDI-related mortality and Figure 2 for 
CDI-related colectomy, where changes in level and slope for the effect of FMT program implementation 
are derived using the segmented logistic regression (SLR) 
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30-day CDI-Related Mortality 
Rates of CDI-related mortality were significantly lower after FMT implementation in the SFCDI 
group (10.2% pre-FMT vs 4.4% post-FMT, P = .02), fulminant CDI group (21.3% pre-FMT vs 9.1% post-
FMT, P = .015), and refractory SFCDI group (43.2% pre-FMT vs. 12.1% post-FMT, P < .001). After 
adjusting for the secular trend with SLR, differences in CDI-related mortality disappeared for SFCDI 
(Figure 1A) and fulminant CDI (Figure 1B). Neither level change nor slope change was statistically 
significant between the two time periods, although the figures suggest an increasing mortality rate 
before FMT program implementation and a decreasing trend afterwards.  
The difference in CDI-related mortality between the pre- and post-FMT periods remained 
significant for the refractory SFCDI group (Figure 1C) after SLR analysis. The inpatient FMT program 
produced an immediate decrease in CDI-related mortality; the odds of mortality after introduction of 
the inpatient FMT program was 0.09 (95%CI: .01-.72, P = .023). There was a rising incidence of CDI-
related mortality in the pre-FMT period compared to a decreasing incidence post-FMT, however the 
change in slope did not achieve significance (P = .07). 
Among patients who received FMT for refractory SFCDI, 42% (21/50) were receiving non-CDI antibiotics 
at time of FMT. CDI-related mortality was not significantly different between the two groups (4.8% with 
vs 6.9% without non-CDI antibiotic use, P = .75).CDI-Related Colectomy 
 Comparing the pre-FMT to post-FMT time period, a lower proportion of hospitalizations had 
CDI-related colectomy in the SFCDI group (6.8% vs 2.7%, P = .041), fulminant subgroup (15.7% vs 5.5%, P 
= 0.017), and refractory SFCDI subgroup (31.8% vs 7.6% P = .001). Secular trends in CDI-related 
colectomy over time are depicted in Figure 2. There appeared to be a down-trending incidence of CDI-
related colectomy prior to FMT program implementation. The downward trend continued after FMT 
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program implementation, leading to no significant differences in the slope or level change in any of the 
three CDI severity groups. 
Other Secondary Outcomes 
 There were no significant changes in length of hospital stay or 30-day readmission rates 
between the pre- and post-FMT time periods across all CDI severity groups (Table 4).  
Discussion 
Our study showed a significantly lower 30-day CDI-related mortality rate in the time period after 
inpatient sequential FMT program became available for patients with SFCDI, including two subgroups 
consisting of fulminant CDI patients and refractory SFCDI patients. After adjusting for the underlying 
secular trend using segmented logistic regression, we found that the FMT program significantly 
decreased CDI-related mortality among patients with refractory SFCDI after its introduction in 2013. In 
the SFCDI group and fulminant CDI subgroup, CDI-related mortality demonstrated a similar rising trend 
pre-FMT and a downward trend post-FMT, however SLR did not yield significance in level or slope 
change. Our segmented regression analysis in the fulminant CDI subgroup was possibly hampered by a 
lack of power due to the small sample size of patients with CDI-related mortality. Specifically, our 
sample size could only provide 30% power for the observed effect in level change, and lower than 10% 
power for the observed effect in slope change.  
Our findings reinforce the notion that FMT reduces mortality among severe CDI patients. In 
Hocquart and colleagues’ recently published cohort of 111 hospitalized patients with severe CDI, 3-
month mortality was 12.1% in those that received FMT and 42.2% in patients who received standard 
antibiotic therapy (P < .0003).23 Our reported rates of mortality in severe CDI patients who did not 
receive FMT are much lower, likely explained by Hocquart’s older patient group (median age 81 versus 
61 years) and a different definition for mortality (3-month all-cause mortality versus 30-day CDI-related 
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mortality). We chose to define mortality within a 30-day post-procedure time frame to allow for direct 
comparison with the surgical literature. Patients with refractory SFCDI in our study would have 
otherwise been considered for surgical intervention due to failure of anti-CDI therapy; their rates of 
mortality compare favorably to previously published post-colectomy mortality rates.10,11  
The rate of CDI-related colectomies was lower after FMT program implementation in the SFCDI, 
fulminant CDI, and refractory SFCDI groups. In a previous observational study, colectomies for severe 
CDI patients decreased after introduction of FMT despite a concurrent increase in CDI-related 
admissions.24 We demonstrated a decreasing trend in the yearly rate of CDI-related colectomies even 
prior to introduction of FMT, a trend that likely reflects improved clinical management of severe CDI and 
changes in surgical concepts on when and whom to intervene. 
 This study supports the use of FMT for treatment of SFCDI, and indicates that patients with 
refractory SFCDI are likely to benefit most. More importantly, it presents FMT as an alternative to 
colectomy in cases of SFCDI where first-line anti-CDI antibiotics are partially or completely ineffective. 
Without FMT, failure of vancomycin or fidaxomicin in cases of refractory SFCDI traditionally leads to one 
of two unfavorable outcomes: continued medical management leading to an 80% mortality rate, or 
salvage colectomy resulting in post-surgical mortality rates in the 30-40% range.2,29   
 While randomized controlled trials are the gold standard for guideline recommendations, 
executing one would be difficult in such a vulnerable population for practical and ethical reasons; 
however, an adaptive trial approach may be appropriate. Emerging evidence suggests that FMT has an 
excellent safety profile and a noticeable benefit over standard medical therapy.21,30,31 Although, 
guidelines suggest that patients with fulminant and refractory SFCDI should consider  colectomy, the 
ideal window for surgical intervention is still ambiguous and there may be a role for FMT pre-colectomy. 
Prolonging surgery to optimize response to medical therapies could inadvertently facilitate deterioration 
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of the patient possibly beyond surgical repair, while premature surgical intervention would 
unnecessarily subject patients to high rates of morbidity post-colectomy. FMT could ameliorate this 
conundrum by serving as a potential cure for refractory SFCDI (thereby avoiding surgery completely). Or, 
even in cases where FMT is incompletely effective, FMT may also serve to quickly stabilize patients prior 
to surgery. Significant improvement in various clinical parameters (eg hemodynamics, vasopressor 
requirement, and leukocytosis) within 24 hours of receiving FMT has been observed in patients with 
SFCDI.32 FMT could also fill the role of salvage therapy in patients whose age, comorbidities, or clinical 
status would otherwise be prohibitive of surgery.33  
 Beyond therapeutic potential, FMT in refractory SFCDI has other practical benefits over 
colectomy. Sequential FMT is more cost effective than colectomy in the treatment of SFCDI, decreasing 
overall treatment costs from $67,422 to $26,700.34 Stool banks for donor material have eliminated the 
1-2 week waiting time for donor stool screening, and the availability of FMT has blossomed such that 
87.5% of the US population lives within 1 hour of an FMT provider.35 
Further investigation is required to clearly define FMT’s role and timing in the clinical course of 
severe and fulminant CDI. However, our study suggests that FMT should be offered to patients with 
severe and fulminant CDI that do not respond to a five-day course of anti-CDI antibiotics, and may be 
considered in lieu or prior to colectomy. Future studies will need to elucidate: a) the optimal FMT 
protocol including route of delivery, timing of first FMT, interval between sequential FMTs, role of 
pseudomembranes in directing therapy, b) the need of co-administration or continuation of anti-CDI 
antibiotic, c) the definition of FMT failure (after how many FMTs should one give up) and optimal timing 
of surgery, d) role and timing of FMT in prevention of CDI-associated end-organ failure such as ileus, 
toxic megacolon, and renal insufficiency, e) role of FMT to stabilize patients prior to undergoing 
colectomy, f) when to offer colectomy in patients that have not improved significantly after multiple 
rounds of FMT. 
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 This study had several limitations. First, this is a single-center experience with skilled 
endoscopists and colorectal surgeons, leading to results that may not be generalizable. Second, this was 
an observational study with a small percentage of mortality or colectomy, which limited our ability to 
account for potential confounding factors when comparing differences in patient characteristics before 
and after FMT program. Third, during the course of our study, there were two significant changes to CDI 
diagnosis and treatment, though unlikely to be confounding factors. Prior to 2010, our institution tested 
for C. difficile using a two-step process consisting of C. difficile antigen glutamate dehydrogenase, 
followed by a confirmatory toxin A and B enzyme immunoassay (EIA), with reported sensitivity 41-92% 
and specificity 94-100%.36 This was changed to PCR with increased sensitivity of 97.7% and specificity of 
99.7%.37 Despite this change and its theoretical improvement in timely delivery of anti-CDI antibiotics, 
rates of severe-complicated CDI and colectomy continued to rise afterwards. Additionally, new ACG 
guidelines for the management and treatment of C. difficile were also released in 2013,5 coincident with 
the initiation of our inpatient FMT program. This could be interpreted as a potential confounding factor 
in our results. However, in comparison to the previously employed guidelines released by the IDSA in 
2010,38 the recommended treatment, antibiotic selection, and classification of severe, complicated, 
and/or refractory disease were not significantly different. Finally, analysis of patient characteristics for 
the refractory SFCDI group revealed that pre-FMT patients had an increased rate of ICU admissions and 
mechanical ventilation. Rapid stabilization of patients after receiving FMT likely accounted for some of 
this difference along with the significantly decreased rate of colectomy. 
 In summary, implementation of an inpatient FMT program was associated with significant 
decreases in CDI-related mortality in patients with refractory SFCDI even after accounting for 
background secular trends FMT should be considered in patients who fail maximal anti-CDI antimicrobial 
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Age (years), mean (SD) 61.1 (16.5) 60.9 (14.9) 61.2 (17.9) .82 
Female, n (%) 212 (49.3%) 110 (53.7%) 102 (45.3%) .085 
Fulminant CDI, n (%) 199 (46.3%) 89 (43.4%) 110 (48.9%) .26 
Refractory CDI, n (%) 110 (25.6%) 44 (21.5%) 66 (29.3%) .062 
Maximum WBC, median (IQR) 22.8 (18.2 - 31.3) 22.8 (18.7 - 31.2) 22.7 (17.5 - 31.3) .31 
Minimum albumin, mean (SD) 2.3 (0.5) 2.3 (0.4) 2.4 (0.5) .71 
Number of Prior CDI episodes, 
median (IQR) 
0.0 (0.0 - 1.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 1.0) <.001 
Charlson comorbidity score, 
mean (SD) 
5.4 (3.0) 5.4 (3.0) 5.4 (3.1) .81 
IBD, n (%) 32 (7.4%) 8 (3.9%) 24 (10.7%) .008 
Immunosuppression, n (%) 90 (20.9%) 45 (22.0%) 45 (20.0%) .62 
Acute kidney injury, n (%) 204 (47.4%) 92 (44.9%) 112 (49.8%) .31 
Fever, n (%) 130 (30.2%) 58 (28.3%) 72 (32.0%) .4 
Hypotension, n (%) 181 (42.1%) 82 (40.0%) 99 (44.0%) .4 
Megacolon, n (%) 22 (5.1%) 8 (3.9%) 14 (6.2%) .28 
Vasopressor use, n (%) 78 (18.1%) 31 (15.1%) 47 (20.9%) .12 
Mental status change, n (%) 120 (27.9%) 52 (25.4%) 68 (30.2%) .26 
Ileus, n (%) 53 (12.3%) 25 (12.2%) 28 (12.4%) .94 
Mechanical ventilation, n (%) 83 (19.3%) 41 (20.0%) 42 (18.7%) .73 
ICU, n (%) 128 (29.8%) 56 (27.3%) 72 (32.0%) .29 
CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; ICU, intensive care unit; IBD, 




Table 2. Patient characteristics of fulminant CDI hospitalizations. 
  
Total 
(N = 199) 
Pre-FMT Program 
(N = 89) 
Post-FMT Program 
(N = 110) 
P Value 
Age (years), mean (SD) 63.8 (15.2) 63.6 (13.4) 63.9 (16.6) .86 
Female, n (%) 100 (50.3%) 53 (59.6%) 47 (42.7%) .018 
Refractory CDI, n (%) 85 (42.7%) 36 (40.4%) 49 (44.5%) .56 
Maximum WBC, median (IQR) 24.6 (18.9 - 39.0) 25.4 (19.7 - 35.1) 24.6 (18.1 - 40.2) .64 
Minimum albumin, mean (SD) 2.4 (0.5) 2.4 (0.5) 2.4 (0.5) .8 
Number of Prior CDI episodes, 
median (IQR) 
0.0 (0.0 - 1.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 2.0) 
<.001 
Charlson comorbidity score, 
mean (SD) 
5.7 (2.9) 5.9 (3.0) 5.6 (2.9) 
.35 
IBD, n (%) 9 (4.5%) 3 (3.4%) 6 (5.5%) .48 
Immunosuppression, n (%) 44 (22.1%) 22 (24.7%) 22 (20.0%) .43 
Acute kidney injury, n (%) 159 (79.9%) 73 (82.0%) 86 (78.2%) .5 
Fever, n (%) 112 (56.3%) 49 (55.1%) 63 (57.3%) .75 
Hypotension, n (%) 181 (91.0%) 82 (92.1%) 99 (90.0%) .6 
Megacolon, n (%) 22 (11.1%) 8 (9.0%) 14 (12.7%) .4 
Vasopressor use, n (%) 78 (39.2%) 31 (34.8%) 47 (42.7%) .26 
Mental status change, n (%) 114 (57.3%) 51 (57.3%) 63 (57.3%) 1 
Ileus, n (%) 53 (26.6%) 25 (28.1%) 28 (25.5%) .68 
Mechanical ventilation, n (%) 79 (39.7%) 40 (44.9%) 39 (35.5%) .17 
ICU, n (%) 112 (56.3%) 47 (52.8%) 65 (59.1%) .37 
CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; ICU, intensive care unit; IBD, 






Table 3. Patient characteristics of refractory SFCDI hospitalizations. 
  
Total 
(N = 110) 
Pre-FMT Program 
(N = 44) 
Post-FMT 
Program 
(N = 66) 
P Value 
Age (years), mean (SD) 64.8 (16.3) 63.8 (13.3) 65.5 (18.2) .59 
Female, n (%) 60 (54.5%) 28 (63.6%) 32 (48.5%) .12 
Fulminant CDI, n (%) 85 (77.3%) 36 (81.8%) 49 (74.2%) .35 
Maximum WBC, median (IQR) 28.9 (20.7 - 42.8) 29.2 (20.7 - 41.8) 28.4 (20.7 - 43.2) .88 
Minimum albumin, mean (SD) 2.5 (0.5) 2.4 (0.5) 2.5 (0.6) .18 
Presence of Prior CDI episodes, median 
(IQR) 
0.5 (0.0 - 2.0) 0.0 (0.0 - 1.0) 1.0 (0.0 - 3.0) <.001 
Charlson comorbidity score, mean (SD) 5.5 (2.9) 6.0 (3.0) 5.2 (2.8) .14 
IBD, n (%) 9 (8.2%) 1 (2.3%) 8 (12.1%) .083 
Immunosuppression, n (%) 21 (19.1%) 10 (22.7%) 11 (16.7%) .43 
Acute kidney injury, n (%) 79 (71.8%) 34 (77.3%) 45 (68.2%) .3 
Fever, n (%) 56 (50.9%) 23 (52.3%) 33 (50.0%) .82 
Hypotension, n (%) 76 (69.1%) 34 (77.3%) 42 (63.6%) .13 
Megacolon, n (%) 18 (16.4%) 7 (15.9%) 11 (16.7%) .92 
Vasopressor use, n (%) 36 (32.7%) 18 (40.9%) 18 (27.3%) .14 
Mental status change, n (%) 58 (52.7%) 28 (63.6%) 30 (45.5%) .061 
Ileus, n (%) 32 (29.1%) 16 (36.4%) 16 (24.2%) .17 
Mechanical ventilation, n (%) 41 (37.3%) 28 (63.6%) 13 (19.7%) <.001 
ICU, n (%) 64 (58.2%) 32 (72.7%) 32 (48.5%) .012 
CDI, Clostridioides difficile infection; FMT, fecal microbiota transplantation; ICU, intensive care unit; IBD, 




Table 4. Summary of outcomes in SFCDI and RCDI hospitalizations. 




Severe or Fulminant CDI  
CDI-related Mortality, n (%) 31 (7.2%) 21 (10.2%) 10 (4.4%) .02 
CDI-related Colectomy, n (%) 20 (4.7%) 14 (6.8%) 6 (2.7%) .041 
Length of Hospital Stay, Median (IQR) 13.0 (8.0 - 21.0) 13.0 (8.0 - 22.0) 13.0 (7.0 - 20.0) .23 
Readmission in 30 days, n (%) 30 (8.4%) 15 (8.8%) 15 (8.0%) .77 
Fulminant CDI 
CDI-related Mortality 29 (14.6%) 19 (21.3%) 10 (9.1%) .015 
CDI-related Colectomy 20 (10.1%) 14 (15.7%) 6 (5.5%) .017 
Length of Hospital Stay, Median (IQR) 14.0 (9.0 - 23.0) 14.0 (9.0 - 23.0) 13.0 (7.0 - 24.0) .74 
Readmission in 30 days 9 (6.1%) 4 (6.3%) 5 (6.0%) 1 
Refractory SFCDI 
CDI-related Mortality, n (%) 27 (24.5%) 19 (43.2%) 8 (12.1%) <.001 
CDI-related Colectomy, n (%) 19 (17.3%) 14 (31.8%) 5 (7.6%) .001 
Length of Hospital Stay, Median (IQR) 13.5 (7.0 - 23.0) 15.0 (9.5 - 25.5) 12.0 (7.0 - 21.0) .16 
Readmission in 30 days, n (%) 5 (6.8%) 1 (4.0%) 4 (8.2%) .66 




Figure 1. Observed and predicted (dotted line) rates of CDI-related mortality before and after FMT 
program initiation. (A) Severe or Fulminant CDI. (B) Fulminant CDI. (C) Refractory SFCDI. 
Figure 2. Observed and predicted (dotted line) rates of CDI-related colectomy before and after FMT 
program initiation. (A) Severe or Fulminant CDI. (B) Fulminant CDI. (C) Refractory SFCDI. 






